Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2
© 2024. The Author(s)..
BACKGROUND: The COVID-19 pandemic is a persistent global threat to public health. As for the emerging variants of SARS-CoV-2, it is necessary to develop vaccines that can induce broader immune responses, particularly vaccines with weak cellular immunity.
METHODS: In this study, we generated a double-layered N-S1 protein nanoparticle (N-S1 PNp) that was formed by desolvating N protein into a protein nanoparticle as the core and crosslinking S1 protein onto the core surface against SARS-CoV-2.
RESULTS: Vaccination with N-S1 PNp elicited robust humoral and vigorous cellular immune responses specific to SARS-CoV-2 in mice. Compared to soluble protein groups, the N-S1 PNp induced a higher level of humoral response, as evidenced by the ability of S1-specific antibodies to block hACE2 receptor binding and neutralize pseudovirus. Critically, N-S1 PNp induced Th1-biased, long-lasting, and cross-neutralizing antibodies, which neutralized the variants of SARS-CoV-2 with minimal loss of activity. N-S1 PNp induced strong responses of CD4+ and CD8+ T cells, mDCs, Tfh cells, and GCs B cells in spleens.
CONCLUSIONS: These results demonstrate that N-S1 PNp vaccination is a practical approach for promoting protection, which has the potential to counteract the waning immune responses against SARS-CoV-2 variants and confer broad efficacy against future new variants. This study provides a new idea for the design of next-generation SARS-CoV-2 vaccines based on the B and T cells response coordination.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Journal of nanobiotechnology - 22(2024), 1 vom: 30. Jan., Seite 44 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Ruiqi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Neutralizing |
---|
Anmerkungen: |
Date Completed 01.02.2024 Date Revised 02.02.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12951-024-02293-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367817616 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367817616 | ||
003 | DE-627 | ||
005 | 20240202232215.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240131s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12951-024-02293-y |2 doi | |
028 | 5 | 2 | |a pubmed24n1278.xml |
035 | |a (DE-627)NLM367817616 | ||
035 | |a (NLM)38291444 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Ruiqi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2 |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.02.2024 | ||
500 | |a Date Revised 02.02.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a BACKGROUND: The COVID-19 pandemic is a persistent global threat to public health. As for the emerging variants of SARS-CoV-2, it is necessary to develop vaccines that can induce broader immune responses, particularly vaccines with weak cellular immunity | ||
520 | |a METHODS: In this study, we generated a double-layered N-S1 protein nanoparticle (N-S1 PNp) that was formed by desolvating N protein into a protein nanoparticle as the core and crosslinking S1 protein onto the core surface against SARS-CoV-2 | ||
520 | |a RESULTS: Vaccination with N-S1 PNp elicited robust humoral and vigorous cellular immune responses specific to SARS-CoV-2 in mice. Compared to soluble protein groups, the N-S1 PNp induced a higher level of humoral response, as evidenced by the ability of S1-specific antibodies to block hACE2 receptor binding and neutralize pseudovirus. Critically, N-S1 PNp induced Th1-biased, long-lasting, and cross-neutralizing antibodies, which neutralized the variants of SARS-CoV-2 with minimal loss of activity. N-S1 PNp induced strong responses of CD4+ and CD8+ T cells, mDCs, Tfh cells, and GCs B cells in spleens | ||
520 | |a CONCLUSIONS: These results demonstrate that N-S1 PNp vaccination is a practical approach for promoting protection, which has the potential to counteract the waning immune responses against SARS-CoV-2 variants and confer broad efficacy against future new variants. This study provides a new idea for the design of next-generation SARS-CoV-2 vaccines based on the B and T cells response coordination | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Coronavirus | |
650 | 4 | |a Nanoparticle | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Subunit vaccine | |
650 | 4 | |a Variants | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
700 | 1 | |a Chang, Zejie |e verfasserin |4 aut | |
700 | 1 | |a Liu, Hongliang |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yanan |e verfasserin |4 aut | |
700 | 1 | |a Li, Minghui |e verfasserin |4 aut | |
700 | 1 | |a Chen, Yilan |e verfasserin |4 aut | |
700 | 1 | |a Fan, Lu |e verfasserin |4 aut | |
700 | 1 | |a Wang, Siqiao |e verfasserin |4 aut | |
700 | 1 | |a Sun, Xueke |e verfasserin |4 aut | |
700 | 1 | |a Liu, Siyuan |e verfasserin |4 aut | |
700 | 1 | |a Cheng, Anchun |e verfasserin |4 aut | |
700 | 1 | |a Ding, Peiyang |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Gaiping |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of nanobiotechnology |d 2003 |g 22(2024), 1 vom: 30. Jan., Seite 44 |w (DE-627)NLM124198341 |x 1477-3155 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:30 |g month:01 |g pages:44 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12951-024-02293-y |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2024 |e 1 |b 30 |c 01 |h 44 |